Telitacicept para la miastenia gravis generalizada refractaria positiva para AChR: un estudio retrospectivo del mundo...

Área de la Ciencia:

• Immunology; Neurology; Pharmacology

Sus antecedentes:

• Refractory acetylcholine receptor-positive generalized myasthenia gravis (AChR+ gMG) presents treatment challenges.; Existing therapies often lack specificity and carry long-term risks.; Telitacicept, a dual inhibitor of B lymphocyte stimulator (BLyS) and proliferation-inducing ligand (APRIL), offers a targeted approach.

Objetivo del estudio:

• To evaluate the efficacy and safety of telitacicept in patients with refractory AChR+ gMG.; To assess the impact of telitacicept on Quantitative Myasthenia Gravis (QMG) scores.; To determine the potential for reducing concomitant immunosuppressive medication use.

Principales métodos:

• A retrospective study involving 42 patients with refractory AChR+ gMG.; Analysis of changes in QMG scores from baseline using mixed-effects models.; Assessment of cumulative response rates, medication reduction, and safety events.

Principales resultados:

• Significant improvement in QMG total scores observed (LS mean change at month 5: -2.24, p<0.001).; Sustained benefits noted in ocular, limb, and bulbar symptoms.; High cumulative response rates (69.9% MGFA-PIS, 73.8% QMG improvement) by 6 months.; Significant reductions in prednisone and other immunosuppressant use.; Telitacicept demonstrated a favorable safety profile.

Conclusiones:

• Telitacicept is effective for treating refractory AChR+ gMG.; The drug may decrease reliance on traditional immunosuppressants.; Real-world data support telitacicept as a valuable treatment option for this patient population.